Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.10 - $121.06
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.14M
Market Cap
$9.61B
Enterprise Value$11.98B
Total Cash (Recent Filing)$949.85M
Total Debt (Recent Filing)$16.59M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
May 12, 2025EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.88
Shares Outstanding128,761,630
10 Day Avg. Volume1,044,966
30 Day Avg. Volume1,139,282
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-21.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-26.11
Forecast
1Y Price Target
$147.17Price Target Upside97.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Vaxcyte News
PremiumCompany Announcements
Vaxcyte’s Earnings Call Highlights Strong Position and Future Growth
PremiumCompany Announcements
Vaxcyte Advances Vaccine Pipeline with Strong Financial Backing---
Bulls Say, Bears Say
Bulls Say
Clinical Data ReleaseA positive Ph2 VAX-24 infants readout could potentially put the stock in the $100+ territory again.
Financial OutlookThe company had $3.1B in cash, cash equivalents and investments, expected to fund milestones into 2027.
Market SentimentInvestor sentiment heading into the Ph2 VAX-24 readout has generally been positive.
Bears Say
Clinical Data RiskA negative Ph2 VAX-24 readout could potentially put the stock in the $50's ballpark.
Macroeconomic ConcernsThere is some lingering concern the negative macro, RFK backdrop may partially mute the potential opportunity on the print.
Market UncertaintyPCVX shares are down roughly -25% attributed entirely to the increased uncertainty tied to anti-vaccine rhetoric.
---
Ownership Overview
0.80% Insiders
46.92% Mutual Funds
0.09% Other Institutional Investors
35.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $58.10 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $9.61B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is May 12, 2025 which is in 48 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Feb 25, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.107 by $0.087.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.04.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 128,761,630 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.107. Following the earnings report the stock price went down -0.882%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
---
Vaxcyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.17 (97.12% Upside)
$147.17 (97.12% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 605.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.37%
12-Months-Change
Fundamentals
Return on Equity
-20.41%
Trailing 12-Months
Asset Growth
150.96%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vaxcyte's strong financial position, significant clinical and manufacturing progress, and proactive regulatory engagement. However, challenges include increased expenses, potential regulatory uncertainties, and the need to meet non-inferiority criteria in clinical studies. Vaxcyte remains optimistic about its pipeline and future growth.Read More>---
PCVX Stock 12 Month Forecast
Average Price Target
$147.17
▲(97.12% Upside)
Technical Analysis
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
18/24 ratings generated profit
1 Year Average Return
+39.90%
reiterated a buy rating 28 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +39.90% per trade.
---